文献速递主动脉疾病

贫血与胸主动脉腔内修复术后更高的死亡率和并发症相关

Anemia is associated with higher mortality and morbidity after thoracic endovascular aortic repair.
PubMed 文献 · J Vasc Surg · 2022-09-08

基于血管质量倡议(Vascular Quality Initiative)数据库回顾性分析3391例胸主动脉腔内修复(TEVAR)患者,中度/重度贫血(女性<10 g/dL,男性<12 g/dL)占28.3%。经倾向评分分层调整后,中度/重度贫血与30天死亡率、院内并发症、术中输血及1年生存率较差独立相关。

要点

  • 中度/重度贫血与30天死亡率调整OR 2.41(95%CI 1.15-5.05;P=.019)相关。
  • 中度/重度贫血与院内并发症调整OR 1.58(95%CI 1.17-2.13;P=.003)相关。
  • 中度/重度贫血与1年生存率较差相关(86.4%±1.3% vs 92.5%±0.6%;log-rank P<.001)。

核心结论

  • 中度或重度贫血与TEVAR术后死亡几率、术后并发症显著增加及1年生存率较差相关。
  • 未来需研究纠正贫血对TEVAR结局的影响。

研究设计与样本

  • 回顾性分析血管质量倡议数据库中2011年1月至2019年12月因主动脉夹层、主动脉瘤、穿透性主动脉溃疡、血肿或血栓行TEVAR的全部患者。
  • 排除动脉瘤破裂、创伤性夹层、急诊修复、治疗主动脉位于5区以远、红细胞增多症、术中或术后输注>4单位浓缩红细胞、血红蛋白水平或手术指征数据缺失者。
  • 最终队列3391例,分为正常/轻度贫血组(女性≥10 g/dL;男性≥12 g/dL)和中度/重度贫血组(女性<10 g/dL;男性<12 g/dL),采用倾向评分分层控制混杂。

主要发现

  • 3391例患者中958例(28.3%)患有中度/重度贫血。
  • 中度/重度贫血与30天死亡率调整OR 2.41(95%CI 1.15-5.05;P=.019)相关。
  • 中度/重度贫血与任何院内并发症调整OR 1.58(95%CI 1.17-2.13;P=.003)相关。
  • 中度/重度贫血与术中输血调整OR 3.81(95%CI 2.68-5.53;P<.001)相关。
  • 中度/重度贫血与TEVAR后第一年生存率显著较差相关(log-rank P<.001;Kaplan-Meier估计1年生存率86.4%±1.3%标准误 vs 92.5%±0.6%标准误),与术后第一年死亡风险增加相关(调整HR 1.81;95%CI 1.16-2.82;P=.009)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is uncertain whether preoperative anemia is independently associated with thoracic endovascular aortic repair (TEVAR) outcomes. Using a national vascular surgery database, we evaluated the associations between preoperative anemia and 30-day mortality, postoperative complications, and 1-year survival for patients undergoing TEVAR. METHODS: We retrospectively analyzed all patients in the Vascular Quality Initiative who had undergone TEVAR for aortic dissection, aortic aneurysm, penetrating aortic ulcer, hematoma, or thrombus between January 2011 and December 2019. We excluded patients with a ruptured aneurysm, traumatic dissection, emergent repair, treated aorta distal to zone 5, polycythemia, transfusion of >4 U of packed red blood cells intraoperatively or postoperatively, and missing data on hemoglobin level or surgical indications. The final study cohort was dichotomized into two groups: normal/mild anemia (women, ≥10 g/dL; men, ≥12 g/dL) and moderate/severe anemia (women, <10 g/dL; male, <12 g/dL). Propensity scores by stratification were used to control for confounding in the analysis of the association between the outcomes of 30-day mortality, postoperative complications, and 1-year survival and a binary indicator variable of moderate/severe anemia vs normal/mild anemia. Kaplan-Meier analysis and log-rank tests were used to compare the 1-year survival between the two groups. A Cox regression model was fitted to assess the associations between anemia and survival outcomes. RESULTS: A total of 3391 patients were analyzed, 958 (28.3%) of whom had had moderate/severe anemia. After adjustment for multiple clinical factors using propensity score stratification, moderate/severe anemia was associated with a 141% increased odds of 30-day mortality (adjusted odds ratio [aOR], 2.41; 95% confidence interval [CI], 1.15-5.05; P = .019), 58% increased odds of any in-hospital complication (aOR, 1.58; 95% CI, 1.17-2.13; P = .003), 281% increased odds of intraoperative transfusion (aOR, 3.81; 95% CI, 2.68-5.53; P < .001). In addition, moderate/severe anemia was associated with significantly worse survival within the first year after TEVAR (log-rank P < .001; 1-year survival rate using Kaplan-Meier estimates, 86.4% ± 1.3% standard error vs 92.5% ± 0.6% standard error) and with an increased risk of mortality in the first postoperative year (adjusted hazard ratio, 1.81; 95% CI, 1.16-2.82; P = .009). CONCLUSIONS: We found that moderate or severe anemia is associated with significantly increased odds of mortality, postoperative complications, and worse 1-year survival after TEVAR. Future studies are needed to evaluate the effect of anemia correction on the outcomes of TEVAR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Yin K, Willie-Permor D, Zarrintan S, et al. Anemia is associated with higher mortality and morbidity after thoracic endovascular aortic repair. J Vasc Surg. 2022. PMID: 36087831. doi:10.1016/j.jvs.2022.08.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。